scholarly journals A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin

2007 ◽  
Vol 104 (39) ◽  
pp. 15394-15399 ◽  
Author(s):  
C. Yang ◽  
J. Feng ◽  
W. Song ◽  
J. Wang ◽  
B. Tsai ◽  
...  
2020 ◽  
Vol 201 ◽  
pp. 108274
Author(s):  
Daniel K. Crawford ◽  
Phillip Vanlandingham ◽  
Susan Schneider ◽  
Matthew M. Goddeeris

2020 ◽  
Author(s):  
Harvey Perez ◽  
May F. Abdallah ◽  
Jose I. Chavira ◽  
Martin T. Egeland ◽  
Karen L. Vo ◽  
...  

AbstractAtaxia Telangiectasia (A-T) is caused by null mutations in the genome stability gene, ATM (A-T mutated). In mice, similar null mutations do not replicate A-T’s characteristic severe ataxia with associated cerebellar dysfunction and atrophy. By increasing genotoxic stress, through the insertion of null mutations in the Atm (nonsense) and related Aptx (knockout) genes, we have generated a novel A-T mouse that first develops mild ataxia, associated with abnormal Purkinje neuron (PN) activity and decreased size, progressing to severe ataxia correlated with further reduced PN activity as well as PN loss and overall cerebellar atrophy. These mice also exhibit high incidences of cancer and immune abnormalities that are all hallmarks of the human disorder. Enabled by the insertion of a clinically relevant nonsense mutation in Atm, we demonstrate that small molecule readthrough (SMRT) compounds can restore ATM production, indicating their potential as a future A-T therapeutic.


Author(s):  
Jenni M. Laitila ◽  
Elyshia L. McNamara ◽  
Catherine D. Wingate ◽  
Hayley Goullee ◽  
Jacob A. Ross ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e45217 ◽  
Author(s):  
Sian E. Piret ◽  
Christopher T. Esapa ◽  
Caroline M. Gorvin ◽  
Rosie Head ◽  
Nellie Y. Loh ◽  
...  

2008 ◽  
Vol 17 (24) ◽  
pp. 3929-3941 ◽  
Author(s):  
Bo Chang ◽  
Md Nawajes A. Mandal ◽  
Venkata R.M. Chavali ◽  
Norman L. Hawes ◽  
Naheed W. Khan ◽  
...  

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199573 ◽  
Author(s):  
Daniel R. McHugh ◽  
Miarasa S. Steele ◽  
Dana M. Valerio ◽  
Alexander Miron ◽  
Rachel J. Mann ◽  
...  

2009 ◽  
Vol 96 (2) ◽  
pp. S44
Author(s):  
Dan Wang ◽  
Charu Shukla ◽  
Xiaoli Liu ◽  
Shirley Yeh ◽  
Ellen Welch ◽  
...  

2016 ◽  
Vol 27 (3-4) ◽  
pp. 111-121 ◽  
Author(s):  
Susanne Diener ◽  
Sieglinde Bayer ◽  
Sibylle Sabrautzki ◽  
Thomas Wieland ◽  
Birgit Mentrup ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jiang Ying Song ◽  
Nobuyuki Saga ◽  
Kunio Kawanishi ◽  
Kentaro Hashikami ◽  
Michiyasu Takeyama ◽  
...  

Abstract X-linked Alport syndrome (XLAS) is a progressive kidney disease caused by genetic abnormalities of COL4A5. Lack of collagen IV α5 chain staining and “basket-weave” by electron microscopy (EM) in glomerular basement membrane (GBM) are its typical pathology. However, the causal relationship between GBM defects and progressive nephropathy is unknown. We analyzed sequential pathology in a mouse model of XLAS harboring a human nonsense mutation of COL4A5. In mutant mice, nephropathy commenced from focal GBM irregularity by EM at 6 weeks of age, prior to exclusive crescents at 13 weeks of age. Low-vacuum scanning EM demonstrated substantial ragged features in GBM, and crescents were closely associated with fibrinoid exudate, despite lack of GBM break and podocyte depletion at 13 weeks of age. Crescents were derived from two sites by different cellular components. One was CD44 + cells, often with fibrinoid exudate in the urinary space, and the other was accumulation of α-SMA + cells in the thickened Bowman’s capsule. These changes finally coalesced, leading to global obliteration. In conclusion, vulnerability of glomerular and capsular barriers to the structural defect in collagen IV may cause non-necrotizing crescents via activation of PECs and migration of interstitial fibroblasts, promoting kidney disease in this model.


Sign in / Sign up

Export Citation Format

Share Document